Disrupting The Traditional Clinical Trial Model

Recorded on 02/06/23

The landscape for clinical research is evolving, with many sponsors looking to leverage technology to address inefficiencies in the traditional site-based clinical trial process and counter the rising cost of developing new therapies. The FDA has been looked favorably on technology-enabled and decentralized clinical trial models even prior to COVID, but the pandemic led to broader adoption of these technologies and models, clearing the way for technology companies to continue disrupting the industry at greater scale. In our view, technology holds the potential to address some longstanding issues in research, including a lack of accessibility and diversity, and may pave the way to a convergence of clinical care and research.

To explore this topic and more, we are joined by David Fishbach, Founder & Principal of Excel Executive Business Advisors, which provides corporate Strategy, operations, and leadership development for technology, life sciences, and healthcare. David’s career has included past leadership experience with many of the leading technology companies that serve the biopharma industry including Veeva Systems, Oracle Health Services and PhaseForward.

For Disclosures, click here bit.ly/3cPHkNW

https://go.td.com/PodcastDisclosure